Mode
Text Size
Log in / Sign up
N/A N=28 Randomized Single-blind Other

Effect of Oligofructose on Appetite in Overweight Subjects

Appetite Regulation · Obesity

Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Subjective Appetite Ratings in Hunger Compared to Baseline — 4.8; 3.6; 3.6; 4.1 cm — p=0.135

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Oligofructose (Dietary_supplement); Placebo (Dietary_supplement)
Age
Adult · 20+ yrs
Sex
All
Sponsor
Imperial College London
Primary completion
Aug 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Subjective Appetite Ratings in Hunger Compared to Baseline
4.8; 3.6; 3.6; 4.1 0.135
PRIMARY
Subjective Appetite Ratings in Fullness Compared to Baseline
4.7; 4.2; 4.2; 4.1 0.688
PRIMARY
Body Weight
83.7; 86; 84.1; 86.3 0.715
PRIMARY
Energy Intake
873.16; 867.61; 760.19; 725.34 0.578
PRIMARY
Gut Hormone PYY
SECONDARY
Body Composition
29.7; 31.1; 29.9; 31.2
SECONDARY
Imaging of Total Adipose Tissue
36.3; 38.4; 37; 38.7
SECONDARY
Plasma Short-chain Fatty Acids Concentrations After Treatment
81.3; 72.8; 5.4; 5.4; 0.9; 0.7 0.024 sig
SECONDARY
Inflammatory Markers
SECONDARY
Glycemic Response
4.8; 4.7
SECONDARY
Serum Insulin
10.2; 9.6
SECONDARY
Breath Hydrogen Levels

Summary

This study seeks to look into the effects of oligofructose supplementation on appetite, energy intake, and body weight and body composition in overweight subjects. Compared to a placebo product (cellulose) oligofructose is hypothesised to suppress hunger and thereby reduce food intake moderately leading to a decrease in body weight.

Eligibility Criteria

Inclusion Criteria

  • Healthy males and females aged 20-50
  • BMI 25-35 kg/m2
  • Weight stable for three months prior to enrollment in study (weight change < 3 kg over a period of three months)
  • Habitual dietary fibre ≤ 25g/day (as assessed by 3-day dietary record)
  • Non-smokers
  • No current or history of endocrine disease, gastrointestinal disease, kidney or liver diseases, cardiovascular disease, pancreatitis, or cancer
  • Hydrogen producers

Exclusion Criteria

  • Use of antibiotic less than three months prior to participation in the study
  • Participation in other research studies in the previous three months
  • Blood donation less than three months before participation in study
  • Anaemia
  • Hypertension
  • Pregnancy or breastfeeding
  • Substance abuse
  • Vegan diet
  • Regular use of prebiotic, probiotic or symbiotic food items/ supplements
  • Intense exercise undertaken for more than 5h per week
  • Metallic or electronic implants e.g. pacemaker, cochlear ear implants, fixed dental braces
  • Claustrophobia
  • Depression
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00912197). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search